Skip Navigation Links

2023 Regular Session
HB403   by Representative Chad Brown      

INSURANCE:  Authorizes substitution of certain biosimilar biological products relative to step therapy or fail first protocols

Current Status:  Signed by the Governor - Act 125


Skip Navigation Links
TextExpand Text
DigestsExpand Digests
VotesExpand Votes
AuthorsExpand Authors

 Date   ChamberJournal
Page
Action sort history by ascending dates
06/06H  Effective date: 08/01/2023.
06/06H  Signed by the Governor. Becomes Act No. 125.
06/01H  Sent to the Governor for executive approval.
05/31S31  Signed by the President of the Senate.
05/31H43  Enrolled and signed by the Speaker of the House.
05/30H3  Received from the Senate without amendments.
05/29S22  Rules suspended. Read by title, passed by a vote of 39 yeas and 0 nays, and ordered returned to the House. Motion to reconsider tabled.
05/26S2  Reported without Legislative Bureau amendments. Read by title and passed to third reading and final passage.
05/25S17  Read by title and referred to the Legislative Bureau.
05/24S9  Reported favorably.
05/16S7  Read second time by title and referred to the Committee on Insurance.
05/15S6  Received in the Senate. Read first time by title and placed on the Calendar for a second reading.
05/11H43  Read third time by title, roll called on final passage, yeas 92, nays 0. Finally passed, title adopted, ordered to the Senate.
05/04H  Scheduled for floor debate on 05/11/2023.
05/03H13  Read by title, ordered engrossed, passed to 3rd reading.
05/02H63  Reported favorably (11-0).
04/10H48  Read by title, under the rules, referred to the Committee on Insurance.
04/03H  First appeared in the Interim Calendar on 4/3/2023.
03/30H  Under the rules, provisionally referred to the Committee on Insurance.
03/30H  Prefiled.




If you experience any technical difficulties navigating this website, click here to contact the webmaster.
P.O. Box 94062 (900 North Third Street) Baton Rouge, Louisiana 70804-9062